Nuvilex Q2 2025 Earnings Results & Report

Nuvilex EPS Results

• Actual EPS: -$0.29
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Nuvilex Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Nuvilex (NASDAQ:PMCB), Inc. was a biotechnology company that developed therapies for cancer and other serious diseases. The company focused on combining cellular therapy with drug-delivery technologies intended to provide localized treatment while limiting exposure to healthy tissue.

Its principal program involved the Cell-in-a-Box technology, which uses encapsulated genetically engineered cells to convert certain chemotherapy prodrugs into active cancer-fighting compounds at or near a tumor. Nuvilex applied this approach primarily to pancreatic cancer, including a planned treatment regimen involving encapsulated cells and ifosfamide.

Nuvilex later changed its name to PharmaCyte Biotech, Inc. and continued development of the Cell-in-a-Box platform under the PharmaCyte Biotech name. Publicly available information about Nuvilex’s operations, geographic reach, and leadership is primarily historical because the company no longer operates under the Nuvilex name.